Q1 EPS Estimate for Esperion Therapeutics Lowered by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for Esperion Therapeutics in a research report issued on Monday, March 16th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of ($0.09) per share for the quarter, down from their previous estimate of ($0.08). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q2 2026 earnings at ($0.06) EPS and Q3 2026 earnings at ($0.05) EPS.

Other research analysts also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. Needham & Company LLC upped their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Piper Sandler started coverage on Esperion Therapeutics in a research report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 target price for the company. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Citizens Jmp increased their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.60.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $2.71 on Wednesday. Esperion Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $4.18. The company’s 50-day moving average is $3.23 and its 200 day moving average is $3.16. The company has a market capitalization of $695.96 million, a P/E ratio of -15.94, a price-to-earnings-growth ratio of 1.93 and a beta of 1.11.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The business had revenue of $168.45 million for the quarter, compared to analyst estimates of $165.12 million.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd increased its stake in Esperion Therapeutics by 17.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 36,744 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 5,492 shares during the last quarter. Invesco Ltd. boosted its position in shares of Esperion Therapeutics by 23.5% during the 4th quarter. Invesco Ltd. now owns 765,118 shares of the biopharmaceutical company’s stock valued at $2,831,000 after acquiring an additional 145,351 shares during the last quarter. Mackenzie Financial Corp grew its holdings in shares of Esperion Therapeutics by 23.5% during the fourth quarter. Mackenzie Financial Corp now owns 336,992 shares of the biopharmaceutical company’s stock worth $1,241,000 after purchasing an additional 64,034 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Esperion Therapeutics in the fourth quarter worth approximately $599,000. Finally, nVerses Capital LLC purchased a new stake in Esperion Therapeutics in the fourth quarter valued at approximately $250,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.